Vafseo Outcomes In-Center Experience

Inclusion Criteria:

• Adult patients greater than or equal to 18 years of age.

• Receiving outpatient in-center hemodialysis at least three times per week forend-stage kidney disease.

• Currently prescribed or eligible for erythropoiesis-stimulating agent based onapproved facility policy

• Understands the procedures and requirements of the study and provides writteninformed consent and authorization for protected health information disclosure.

Exclusion Criteria:

• Contraindication to receive vadadustat or any of its known constituents per USPI.

• Cirrhosis or active, acute liver disease. Concomitant use of any hypoxia-induciblefactor prolyl-hydroxylases or OAT1/OAT3 inhibitors (probenacid, rifampicin,gemfibrozil, or teriflunomide).

• Unable to comply with study requirements or in the opinion of a healthcare provideror a member of the central study team, not clinically stable to participate in thestudy.

• Pregnant at time of consent (per subject self-report).